GOLGA2 Antibody

What is GOLGA2/GM130 and what cellular functions does it regulate?

GOLGA2 (Golgin subfamily A member 2), also known as GM130, is a 130 kDa cis-Golgi matrix protein localized primarily at the cytoplasmic face of the cis-Golgi membrane. It functions as a peripheral membrane protein highly bound to the Golgi membrane . GOLGA2/GM130 plays critical roles in:

• Stacking of Golgi cisternae and maintenance of Golgi structure

• Vesicular transport, particularly in ER-to-Golgi trafficking

• Glycosylation of secretory and membrane proteins

• Cell cycle progression

• Cell polarization and directed cell migration

• Mitotic spindle pole assembly and centrosome organization

GOLGA2/GM130 acts together with partner proteins including p115, giantin, GRASP65, and Rab GTPases to maintain Golgi integrity and function .

Why does GOLGA2/GM130 show variable molecular weights in experimental applications?

While the calculated molecular weight of GOLGA2/GM130 is approximately 111 kDa, it is commonly observed at ~130 kDa in experimental applications . This discrepancy can be attributed to:

The observed molecular weight variations may result from:

• Post-translational modifications

• Species differences (human vs. mouse/rat)

• Sample preparation methods (reducing vs. non-reducing conditions)

• Resolution limitations of the gel system used

Always include appropriate positive controls (MCF-7, HeLa, ZR-75 cell lysates) which consistently show GOLGA2 expression .

How should I select the optimal GOLGA2 antibody for my specific application?

Selection criteria should be based on:

• Application compatibility: Choose antibodies validated for your specific application

  • For Western blotting: Consider antibodies with clear single-band detection (e.g., MAB81991, 11308-1-AP)

  • For immunofluorescence: Select antibodies with distinct Golgi staining patterns (e.g., ab195303, CL647-11308)

• Host species: Consider your experimental design and secondary antibody compatibility

  • Rabbit antibodies: Most common (e.g., 11308-1-AP, HPA021230)

  • Rat antibodies: Available for co-staining with rabbit antibodies (e.g., 54102)

• Clonality:

  • Monoclonal: Higher specificity, batch consistency (e.g., MAB81991, ab195303)

  • Polyclonal: Broader epitope recognition, potentially higher sensitivity (e.g., AF8199, 11308-1-AP)

• Reactivity: Ensure compatibility with your species of interest

  • Human, mouse, rat cross-reactivity is common for many GOLGA2 antibodies

  • Consider sequence homology (e.g., mouse immunogen showing 85.7% homology to human sequence)

What are the recommended protocols for optimizing GOLGA2 antibody staining in immunofluorescence?

For optimal results in immunofluorescence applications:

• Fixation options:

  • 4% paraformaldehyde (10 min) for structure preservation

  • 80% methanol (5 min) as an alternative fixation method

• Permeabilization:

  • 0.1% PBS-Tween for 20 minutes

  • Alternative: 0.2% Triton X-100 in PBS (5 min)

• Blocking:

  • 10% normal serum (matching secondary antibody host)

  • 0.3M glycine to reduce non-specific binding

  • 0.5-1% BSA in PBS

• Antibody dilutions:

  • Primary: 1:50-1:500 for most immunofluorescence applications

  • For conjugated antibodies (e.g., CL647-11308): 1:50-1:500

  • Always titrate to determine optimal concentration

• Controls:

  • Include positive control cells with known GOLGA2 expression (HeLa, HepG2, MCF-7)

  • Use isotype controls (e.g., rabbit IgG at equivalent concentration)

  • Include untreated/unstained samples to assess autofluorescence

• Co-staining markers:

  • Consider co-staining with other Golgi markers to validate specificity

  • Use different host species antibodies to avoid cross-reactivity

What are common challenges in Western blot detection of GOLGA2/GM130 and how can they be resolved?

For optimal results:

• For Western blot, recommended dilutions range from 1:5000 to 1:50000

• Consider using 12-230 kDa separation systems for better resolution

• For difficult samples, try Simple Western™ technology as an alternative approach

How can I distinguish between specific and non-specific binding when interpreting GOLGA2 staining patterns?

Distinguishing specific from non-specific staining requires multiple validation approaches:

• Characteristic staining pattern:

  • Specific GOLGA2 staining appears as perinuclear, ribbon-like structures corresponding to the Golgi apparatus

  • Non-specific staining may appear diffuse, uniform, or present in unexpected cellular compartments

• Controls to implement:

  • Positive controls: Known GOLGA2-expressing cell lines (HeLa, MCF-7, HepG2)

  • Negative controls:

    • Isotype-matched irrelevant antibodies (e.g., rabbit IgG)

    • Primary antibody omission

    • GOLGA2 knockdown cells (using siRNA or shRNA)

• Co-localization analysis:

  • Co-stain with established Golgi markers

  • Specific GOLGA2 staining should overlap with cis-Golgi compartments

• Functional validation:

  • Treatment with Brefeldin A (disrupts Golgi) should alter GOLGA2 staining pattern

  • Mitotic cells should show different GOLGA2 distribution (Golgi fragmentation)

• Quantitative assessment:

  • Compare signal-to-noise ratios across different antibody concentrations

  • Establish thresholds for positive staining based on control samples

How does GOLGA2/GM130 contribute to disease mechanisms and what experimental approaches can investigate this?

GOLGA2/GM130 has been implicated in several pathological conditions:

• Neurodevelopmental disorders:

  • A homozygous frameshift mutation in GOLGA2 was identified in a patient with developmental delay, seizures, progressive microcephaly, and muscular dystrophy

  • Experimental approach: Zebrafish knockdown models showed skeletal muscle disorganization and microcephaly, recapitulating the human phenotype

• Cancer progression:

  • Downregulation of GOLGA2/GM130 suppresses lung tumorigenesis by:

    • Inhibiting glycosylation

    • Reducing cell proliferation

    • Facilitating autophagic cell death

  • Experimental approach: shRNA-mediated silencing in A549 cells and K-ras LA1 mice models

• Autophagy regulation:

  • GOLGA2/GM130 knockdown induces autophagy in cancer cells

  • Decreased GOLGA2/GM130 causes:

    • Increased LC3-II/LC3-I ratio (autophagosome marker)

    • Formation of autophagosomes and accumulation of autophagic vesicles

  • Experimental approach: Transmission electron microscopy and LC3 immunofluorescence assays

• Congenital disorders of glycosylation:

  • GOLGA2 dysfunction leads to glycosylation defects

  • Experimental approach: Monitor protein glycosylation using glycosylation-specific antibodies (e.g., RL2)

What are the latest methodological advances for studying GOLGA2/GM130 dynamics in living cells?

Recent methodological advances include:

• Live-cell imaging approaches:

  • Fluorescently tagged GOLGA2 constructs for real-time monitoring

  • Photoactivatable or photoconvertible GOLGA2 fusions for pulse-chase experiments

  • FRAP (Fluorescence Recovery After Photobleaching) to study GOLGA2 dynamics within the Golgi

• Super-resolution microscopy:

  • STED (Stimulated Emission Depletion) microscopy for nanoscale visualization

  • STORM/PALM for single-molecule localization of GOLGA2

  • Expansion microscopy to physically enlarge samples for improved resolution

• Proximity labeling methods:

  • BioID or TurboID fused to GOLGA2 to identify proximal interaction partners

  • APEX2-GOLGA2 for electron microscopy-compatible proximity labeling

• Optogenetic approaches:

  • Light-inducible GOLGA2 recruitment or sequestration

  • Optogenetic control of GOLGA2 interactions with binding partners

• CRISPR-based technologies:

  • CRISPR-Cas9 genome editing to generate endogenous fluorescent GOLGA2 fusions

  • CRISPRi/CRISPRa for tunable control of GOLGA2 expression

  • Base or prime editing to introduce specific point mutations

What complementary techniques should be used to validate findings from GOLGA2 antibody-based experiments?

Robust validation requires multiple complementary approaches:

• Gene expression analysis:

  • RT-PCR and qPCR to quantify GOLGA2 mRNA levels

  • RNA-seq for transcriptome-wide effects of GOLGA2 manipulation

• Protein-based verification:

  • Multiple antibodies targeting different epitopes of GOLGA2

  • Mass spectrometry to verify GOLGA2 protein identity and modifications

  • Protein-protein interaction studies (co-IP, proximity labeling)

• Genetic manipulation:

  • siRNA or shRNA knockdown of GOLGA2

  • CRISPR-Cas9 knockout or knockin

  • Rescue experiments with wild-type or mutant GOLGA2 constructs

• Functional assays:

  • Vesicular transport assays

  • Glycosylation analysis of secretory proteins

  • Cell cycle progression monitoring

  • Mitotic spindle formation analysis

• Ultrastructural analysis:

  • Transmission electron microscopy to assess Golgi morphology

  • Immuno-electron microscopy for nanoscale localization

• Physiological models:

  • Animal models (zebrafish, mice) to assess in vivo relevance

  • Patient-derived cells or tissues when available

How can I interpret changes in GOLGA2/GM130 localization or expression under different experimental conditions?

Interpreting GOLGA2/GM130 changes requires consideration of several parameters:

• Golgi fragmentation:

  • Normal: Ribbon-like perinuclear Golgi structure

  • Altered: Dispersed punctate structures throughout the cytoplasm

  • Significance: May indicate cell cycle changes, stress responses, or pathological conditions

• Expression level changes:

  • Quantification methods: Western blot densitometry, immunofluorescence intensity

  • Controls: Normalize to housekeeping proteins and total protein loading

  • Interpretation: Changes may reflect altered Golgi function, stress response, or compensatory mechanisms

• Post-translational modifications:

  • Phosphorylation at Ser-37 by CDK1 during mitosis inhibits interaction with p115/USO1

  • Other modifications may affect protein stability, localization, or function

  • Detection: Phospho-specific antibodies or mobility shift in Western blots

• Co-localization changes:

  • Analysis with other Golgi markers

  • Quantitative co-localization metrics (Pearson's coefficient, Manders' overlap)

  • Interpretation: Changes may indicate Golgi subdomain reorganization

• Experimental context considerations:

  • Cell cycle stage (GOLGA2 function changes during mitosis)

  • Stress conditions (nutrient deprivation, ER stress)

  • Cell type-specific differences in Golgi organization

  • Disease models (cancer, neurodegeneration)

For rigorous analysis, implement quantitative approaches and appropriate statistical tests when comparing GOLGA2/GM130 patterns across experimental conditions.